Mostrando 10 resultados de: 15
Filtros aplicados
Subtipo de publicación
Other(15)
Área temáticas
Enfermedades(7)
Farmacología y terapéutica(6)
Microorganismos, hongos y algas(6)
Medicina forense; incidencia de enfermedades(4)
Actuaciones públicas(1)
Área de conocimiento
Medicina veterinaria(8)
Inmunología(6)
Infección(5)
Microbiología(1)
Salud Pública(1)
Origen
google(15)
A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN)
OtherAbstract: Protection against canine kala-azar was investigated in naturally exposed dogs of an endemic area, vPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleFML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine
OtherAbstract: The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical andPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleEffective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
OtherAbstract: The potential effect of the fucose mannose ligand (FML)-vaccine on immunotherapy of canine visceralPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleHuman Visceral Leishmaniasis: Ethical and Legal Reflections on the Canine Reservoir Control in Brazil
OtherAbstract: Brazil currently faces difficulties in combating human visceral leishmaniasis. According to the WorlPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleParaguai de Souza E, Luz KG, Palatnik M, et al. A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Gonçalo do Amarante, RN)
OtherAbstract:Palabras claves:Autores:Gulnara Borja-CabreraFuentes:googleIgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis.
OtherAbstract: Canine antibody I-G. IgG1 and IgG2 anti-FML responses were investigated in dogs vaccinated with thePalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleImmunogenicity assay of the Leishmune® vaccine against canine visceral leishmaniasis in Brazil
OtherAbstract: Leishmune® is the industrialized version of the FML-saponin vaccine which has been shown to developPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleImmunotherapy with the saponin enriched-Leishmune® vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis
OtherAbstract: Leishmune®, the first licensed vaccine for prophylaxis against canine visceral leishmaniasis (CVL) aPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleLeishmune® vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs
OtherAbstract: Leishmune® vaccine is the first licensed vaccine against canine visceral leishmaniasis. It containsPalabras claves:Autores:Gulnara Borja-CabreraFuentes:googleLong lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN)
OtherAbstract: Naturally exposed dogs of an endemic area were vaccinated with the fucose mannose ligand (FML) antigPalabras claves:Autores:Gulnara Borja-CabreraFuentes:google